NCT07351864Active, not recruitingPhase 4
Finerenone Plus SGLT2 Inhibitors in Heart Failure
Impact of Finerenone in Combination With Sodium Glucose Cotransporter-2 Inhibitor in Patients With Heart Failure
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure. The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone. Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 28 Dec 2025
- Start date
- 18 Jan 2026
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Mansoura University
- Diseases
- Heart failure
- NCT number
- NCT07351864
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From 18 Jan 2026 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with stroke.
- HF secondary to congenital heart disease or pulmonary hypertension
- Patients needing cardiac transplantation.
- Known allergy to study medications.
Lab values
- eGFR \<25 mL/min.
Other
- Use intravenous inotropes.
Who the study is looking for
- Male and female patients aged 18 - 65 years.
- Newly diagnosed with HFrEF or HFpEF.
- Clinically stable and eligible to start SGLT2 inhibitors ± Finerenone therapy.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mansoura University Hospitals, Cardiology Department (Specialized Medical Hospital) Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.